KEAP1 and cancer: For instance, Replogle et al. combined CRISPR/Cas9-based genetic screening and metabolomic analyses to show that Keap1/Nrf2-mutant cancers are dependent on increased glutaminolysis, and this key insight can be therapeutically exploited for cancer treatment (Romero et al., 2017).